Absence of fosfomycin resistance in gastrointestinal Escherichia coli following fosfomycin therapy.
作者信息
Mettus Roberta T, Bowler Sarah L, Kantz Serena F, McElheny Christi L, Pasculle A William, Doi Yohei
机构信息
Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Clinical Microbiology Laboratory, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
出版信息
J Glob Antimicrob Resist. 2018 Sep;14:109-110. doi: 10.1016/j.jgar.2018.06.015. Epub 2018 Jun 30.
Abstract
摘要
相似文献
1
Absence of fosfomycin resistance in gastrointestinal Escherichia coli following fosfomycin therapy.磷霉素治疗后胃肠道大肠杆菌中未出现磷霉素耐药性。
J Glob Antimicrob Resist. 2018 Sep;14:109-110. doi: 10.1016/j.jgar.2018.06.015. Epub 2018 Jun 30.
2
Identification and characterisation of fosfomycin resistance in Escherichia coli urinary tract infection isolates from Australia.鉴定和特征分析澳大利亚大肠埃希菌尿路感染分离株中的磷霉素耐药性。
Int J Antimicrob Agents. 2020 Oct;56(4):106121. doi: 10.1016/j.ijantimicag.2020.106121. Epub 2020 Jul 31.
3
In-vitro susceptibility of quinolone-resistant clinical isolates of Escherichia coli to fosfomycin trometamol.耐喹诺酮类临床分离大肠杆菌对磷霉素氨丁三醇的体外敏感性
J Chemother. 2002 Jun;14(3):237-40. doi: 10.1179/joc.2002.14.3.237.
4
[Fosfomycin: an underrated antibiotic for urinary tract infections due to Escherichia coli].磷霉素：一种被低估的用于治疗大肠埃希菌所致尿路感染的抗生素
Enferm Infecc Microbiol Clin. 2001 Dec;19(10):462-6. doi: 10.1016/s0213-005x(01)72702-4.
5
Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.社区中磷霉素使用的增加与产超广谱β-内酰胺酶（ESBL）大肠埃希菌对磷霉素耐药性的平行增加。
J Antimicrob Chemother. 2010 Nov;65(11):2459-63. doi: 10.1093/jac/dkq346. Epub 2010 Sep 16.
6
Experiences in fosfomycin susceptibility testing and resistance mechanism determination in Escherichia coli from urinary tract infections in the UK.英国尿路感染大肠埃希菌磷霉素药敏试验及耐药机制研究的体会。
J Med Microbiol. 2019 Feb;68(2):161-168. doi: 10.1099/jmm.0.000901. Epub 2018 Dec 13.
7
Pharmacodynamic Evaluation of Fosfomycin against Escherichia coli and Klebsiella spp. from Urinary Tract Infections and the Influence of pH on Fosfomycin Activities.磷霉素对尿路感染患者分离的大肠埃希菌和克雷伯菌属的药效学评价及pH对磷霉素活性的影响
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.02498-16. Print 2017 Aug.
8
Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.碳青霉烯类药物与磷霉素氨丁三醇治疗产超广谱β-内酰胺酶大肠埃希菌相关复杂性下尿路感染的疗效比较
J Chemother. 2010 Oct;22(5):355-7. doi: 10.1179/joc.2010.22.5.355.
9
CTX-M-15-producing urinary Escherichia coli O25b-ST131-phylogroup B2 has acquired resistance to fosfomycin.产CTX-M-15的泌尿道大肠杆菌O25b-ST131-菌系B2已获得对磷霉素的耐药性。
J Antimicrob Chemother. 2009 Oct;64(4):712-7. doi: 10.1093/jac/dkp288. Epub 2009 Aug 11.
10
Urinary Tract Conditions Affect Fosfomycin Activity against Escherichia coli Strains Harboring Chromosomal Mutations Involved in Fosfomycin Uptake.尿路条件影响磷霉素对携带参与磷霉素摄取的染色体突变的大肠杆菌菌株的活性。
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01899-17. Print 2018 Jan.
本文引用的文献
1
Fosfomycin and Comparator Activity Against Select Enterobacteriaceae, Pseudomonas, and Enterococcus Urinary Tract Infection Isolates from the United States in 2012.2012年美国磷霉素与对照药物对部分肠杆菌科细菌、铜绿假单胞菌及肠球菌尿路感染分离株的活性比较
Infect Dis Ther. 2017 Jun;6(2):233-243. doi: 10.1007/s40121-017-0150-5. Epub 2017 Mar 11.
2
Activity of fosfomycin and comparison of several susceptibility testing methods against contemporary urine isolates.磷霉素活性及几种药敏试验方法对当代尿液分离株的比较。
Int J Antimicrob Agents. 2015 Dec;46(6):642-7. doi: 10.1016/j.ijantimicag.2015.08.012. Epub 2015 Sep 30.
3
Susceptibility to alternative oral antimicrobial agents in relation to sequence type ST131 status and Coresistance phenotype among recent Escherichia coli isolates from U.S. veterans.美国退伍军人近期分离的大肠杆菌中，与序列型 ST131 状态及共同耐药表型相关的，对其他口服抗菌药物的敏感性。
Antimicrob Agents Chemother. 2013 Oct;57(10):4856-60. doi: 10.1128/AAC.00650-13. Epub 2013 Jul 22.
4
Biological costs and mechanisms of fosfomycin resistance in Escherichia coli.大肠杆菌中磷霉素耐药性的生物学代价及机制
Antimicrob Agents Chemother. 2003 Sep;47(9):2850-8. doi: 10.1128/AAC.47.9.2850-2858.2003.
5
Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant gram-negative bacilli from gastrointestinal flora.氟喹诺酮类药物给药对胃肠道菌群中耐氟喹诺酮革兰氏阴性杆菌出现的影响。
Clin Infect Dis. 2001 Jan;32(1):162-6. doi: 10.1086/317551. Epub 2000 Dec 11.
Zotero 插件